Interleukin-33 in Comorbidity of Bronchial Asthma and Arterial Hypertension
Gespeichert in:
| Titel: | Interleukin-33 in Comorbidity of Bronchial Asthma and Arterial Hypertension |
|---|---|
| Autoren: | Iryna Valilshchykova, Tatyana Ambrosova |
| Quelle: | Archive of Clinical Medicine; Vol. 31 No. 1 (2025); 4-8 Архів клінічної медицини; Том 31 № 1 (2025); 4-8 |
| Verlagsinformationen: | Ivano-Frankivsk National Medical University, 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | Arterial hypertension, Systemic inflammation, Comorbidity, Interleukin-33, Bronchial asthma |
| Beschreibung: | Bronchial asthma (BA) ranks first in terms of prevalence, severity, difficulties in diagnosis, treatment and rehabilitation and continues to be one of the main health problems in the world. According to the latest WHO data, 235-300 million people worldwide are diagnosed with asthma. There is a forecast that this figure may reach 400 million by 2025. In recent years, asthma incidence rates in different countries of the world have ranged from 1 to 18%. In this study, we aimed to evaluate the diagnostic significance of interleukin-33 in patients with bronchial asthma combined with arterial hypertension. Literature data regarding the pathogenetic features of bronchial asthma in combination with arterial hypertension and the role of interleukin-33 in the comorbidity of these diseases today were analyzed. An increase in IL-33 levels may be a harbinger of exacerbations of bronchial asthma or the development of hypertension. Measurement of IL-33 can help in the selection of therapeutic strategies, especially in cases where standard treatment does not give the desired result, and additional correction of inflammatory processes is required. In general, IL-33 may be a useful biomarker for early detection and monitoring of patients with comorbidity of BA and AG, although its full use in clinical practice requires further studies confirming these results. Taking into account the global data, IL-33 may be a useful biomarker for early detection and monitoring of patients with BA and AG comorbidity, although further studies confirming these results are necessary for its full use in clinical practice. |
| Publikationsart: | Article |
| Dateibeschreibung: | application/pdf |
| ISSN: | 2414-9853 2312-7007 |
| DOI: | 10.21802/acm.2025.1.7 |
| Zugangs-URL: | https://ifnmujournal.com/acm/article/view/acm202517 |
| Rights: | CC BY NC |
| Dokumentencode: | edsair.doi.dedup.....2982f1810f1f74276ffec91e54e802af |
| Datenbank: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | Bronchial asthma (BA) ranks first in terms of prevalence, severity, difficulties in diagnosis, treatment and rehabilitation and continues to be one of the main health problems in the world. According to the latest WHO data, 235-300 million people worldwide are diagnosed with asthma. There is a forecast that this figure may reach 400 million by 2025. In recent years, asthma incidence rates in different countries of the world have ranged from 1 to 18%. In this study, we aimed to evaluate the diagnostic significance of interleukin-33 in patients with bronchial asthma combined with arterial hypertension. Literature data regarding the pathogenetic features of bronchial asthma in combination with arterial hypertension and the role of interleukin-33 in the comorbidity of these diseases today were analyzed. An increase in IL-33 levels may be a harbinger of exacerbations of bronchial asthma or the development of hypertension. Measurement of IL-33 can help in the selection of therapeutic strategies, especially in cases where standard treatment does not give the desired result, and additional correction of inflammatory processes is required. In general, IL-33 may be a useful biomarker for early detection and monitoring of patients with comorbidity of BA and AG, although its full use in clinical practice requires further studies confirming these results. Taking into account the global data, IL-33 may be a useful biomarker for early detection and monitoring of patients with BA and AG comorbidity, although further studies confirming these results are necessary for its full use in clinical practice. |
|---|---|
| ISSN: | 24149853 23127007 |
| DOI: | 10.21802/acm.2025.1.7 |